Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: results from the open-label, multicentre, non-interventional BRAWO study - Lüftner, Diana; Schütz, Florian; Schneeweiss, Andreas; Hartkopf, Andreas; Bloch, Wilhelm; Decker, Thomas; Uleer, Christoph; Stötzer, Oliver; Foerster, Frank; Schmidt, Marcus; Mundhenke, Christoph; Tesch, Hans; et al. (International journal of cancer, 2024)
Zuerst veröffentlicht: 06. März 2024